ArticleAmerican journal of cancer research2025
In vivo antibody library screening identifies PKM2-targeting M1 antibody with antitumor activity in melanoma.
Article in American journal of cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study, we introduce an innovative in vivo antibody screening method to identify antibodies that can inhibit melanoma cell growth and induce apoptosis. By using a lentiviral ScFv library, we developed a platform that allows for the direct suppression of melanoma cell proliferation within a living mouse model. Through this approach, we identified the M1 antibody, which targets PKM2, a key protein involved in tumor progression. The M1 antibody was found to significantly inhibit melanoma cell growth by disrupting the function of PKM2. Although PKM2 is widely recognized as an important factor in various cancers, no commercial therapeutic agents currently target this protein. Our findings indicate that the in vivo antibody screening method is a reliable and effective approach for isolating antibodies for melanoma therapy. Moreover, the M1 antibody shows great potential as a promising candidate for developing novel treatments for human melanoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.